Table 4 Univariate and multivariate analyses of progression-free survival (PFS) and overall survival (OS) in CA-TTF group patients

Age

Median (Min, Max)

53.0 (22.0,76.0)

1.01 (0.98–1.04, p = 0.523)

1.04 (1.00–1.07, p = 0.048)

1.01 (0.96–1.07, p = 0.670)

1.01 (0.94–1.09, p = 0.691)

Sex

Female

11 (29.7)

-

-

-

-

Male

26 (70.3)

3.29 (1.22–8.88, p = 0.019)

3.72 (1.08–12.79, p = 0.037)

3.63 (1.18–11.18, p = 0.025)

4.74 (1.12–20.09, p = 0.035)

Extent of resection

GTR

26 (70.3)

-

-

-

-

STR/Biopsy

11 (29.7)

2.13 (0.92–4.89, p = 0.076)

1.65 (0.67–4.06, p = 0.274)

5.28 (1.47–18.91, p = 0.011)

3.37 (1.00–11.32, p = 0.050)

MGMT promoter region methylation

Methylated

15 (40.5)

-

-

-

-

Unmethylated

22 (59.5)

1.77 (0.76–4.12, p = 0.183)

1.40 (0.56–3.51, p = 0.477)

2.34 (0.79–6.95, p = 0.125)

3.57 (0.88–14.53, p = 0.076)

TERT promoter mutation status

Mutation

25 (67.6)

-

-

-

-

Wild-type

12 (32.4)

0.51 (0.20–1.28, p = 0.152)

0.85 (0.34–2.14, p = 0.730)

0.32 (0.08–1.26, p = 0.104)

0.39 (0.06–2.43, p = 0.311)

Baseline KPS ≥ 90

NO

11 (29.7)

-

-

-

-

YES

26 (70.3)

0.64 (0.28–1.44, p = 0.280)

0.45 (0.19–1.09, p = 0.077)

1.29 (0.41–4.00, p = 0.665)

0.53 (0.14–1.98, p = 0.346)

Patient compliance with TTF (hours/day)

Median (Min, Max)

20.12 (16.8,23.0)

0.82 (0.61–1.10, p = 0.191)

0.93 (0.68–1.29, p = 0.669)

0.68 (0.49–0.93, p = 0.016)

1.03 (0.70–1.52, p = 0.872)

Duration of TTF(months)

Median (Min, Max)

10.0 (1.0,31.0)

0.97 (0.93–1.02, p = 0.260)

0.93 (0.87–0.99, p = 0.019)

0.94 (0.86–1.03, p = 0.203)

0.89 (0.81–0.98, p = 0.013)